Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Prostate Neuroendocrine Carcinoma”

87 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 87 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02893917
What this trial is testing

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Who this might be right for
Advanced Prostate Adenocarcinoma With Neuroendocrine DifferentiationCastration-Resistant Prostate CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+3 more
National Cancer Institute (NCI) 90
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Testing effectiveness (Phase 2)Active Not RecruitingNCT04592237
What this trial is testing

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Who this might be right for
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+3 more
M.D. Anderson Cancer Center 120
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Not applicableWithdrawnNCT04985357
What this trial is testing

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Who this might be right for
Stage III Breast CancerStage IV Breast CancerStage III Lung Cancer+35 more
Travera Inc
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Early research (Phase 1)Study completedNCT01155258
What this trial is testing

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Who this might be right for
Extensive Stage Small Cell Lung CancerHereditary ParagangliomaMale Breast Cancer+45 more
University of Southern California 19
Early research (Phase 1)Active Not RecruitingNCT03983954
What this trial is testing

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Who this might be right for
ER+ Breast CancerOvarian CancerCervical Squamous Cell Carcinoma+17 more
NeoTX Therapeutics Ltd. 120
Early research (Phase 1)Study completedNCT00004074
What this trial is testing

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Who this might be right for
Advanced Adult Primary Liver CancerAnaplastic Thyroid CancerBone Metastases+124 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Study completedNCT01799278
What this trial is testing

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Who this might be right for
Small Cell Prostate CancerNeuroendocrine Prostate CancerProstate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
Weill Medical College of Cornell University 60
Early research (Phase 1)Study completedNCT01183663
What this trial is testing

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 180
Early research (Phase 1)Study completedNCT03849469
What this trial is testing

XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Who this might be right for
MelanomaCervical CarcinomaPancreatic Carcinoma+20 more
Xencor, Inc. 78
Not applicableStudy completedNCT00477919
What this trial is testing

E-MOSAIC Electronic Tool to Monitor Symptoms

Who this might be right for
Cancer
Swiss Cancer Institute 264
Not applicableUnknownNCT04628806
What this trial is testing

Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells

Who this might be right for
Melanoma Stage IVSarcomaSquamous Cell Carcinoma+3 more
Charite University, Berlin, Germany 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT04140526
What this trial is testing

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Who this might be right for
Non Small Cell Lung CancerAdvanced Solid TumorMetastatic Melanoma+16 more
OncoC4, Inc. 733
Early research (Phase 1)Ended earlyNCT02628535
What this trial is testing

Safety Study of MGD009 in B7-H3-expressing Tumors

Who this might be right for
MesotheliomaBladder CancerMelanoma+10 more
MacroGenics 67
Not applicableStudy completedNCT00253708
What this trial is testing

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Cancer
Beth Israel Deaconess Medical Center 39
Testing effectiveness (Phase 2)Looking for participantsNCT07179783
What this trial is testing

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Who this might be right for
Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital 28
Early research (Phase 1)Study completedNCT04148937
What this trial is testing

The CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 52
Not applicableLooking for participantsNCT06967961
What this trial is testing

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Who this might be right for
Urothelial CarcinomaRenal CancerProstate Adenocarcinoma+7 more
Institut Claudius Regaud 450
Load More Results